Uniqure NV
NASDAQ:QURE
US |
Fubotv Inc
NYSE:FUBO
|
Media
|
|
US |
Bank of America Corp
NYSE:BAC
|
Banking
|
|
US |
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
|
US |
C
|
C3.ai Inc
NYSE:AI
|
Technology
|
US |
Uber Technologies Inc
NYSE:UBER
|
Road & Rail
|
|
CN |
NIO Inc
NYSE:NIO
|
Automobiles
|
|
US |
Fluor Corp
NYSE:FLR
|
Construction
|
|
US |
Jacobs Engineering Group Inc
NYSE:J
|
Professional Services
|
|
US |
TopBuild Corp
NYSE:BLD
|
Consumer products
|
|
US |
Abbott Laboratories
NYSE:ABT
|
Health Care
|
|
US |
Chevron Corp
NYSE:CVX
|
Energy
|
|
US |
Occidental Petroleum Corp
NYSE:OXY
|
Energy
|
|
US |
Matrix Service Co
NASDAQ:MTRX
|
Construction
|
|
US |
Automatic Data Processing Inc
NASDAQ:ADP
|
Technology
|
|
US |
Qualcomm Inc
NASDAQ:QCOM
|
Semiconductors
|
|
US |
Ambarella Inc
NASDAQ:AMBA
|
Semiconductors
|
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
52 Week Range |
3.78
10.12
|
Price Target |
|
We'll email you a reminder when the closing price reaches USD.
Choose the stock you wish to monitor with a price alert.
Fubotv Inc
NYSE:FUBO
|
US | |
Bank of America Corp
NYSE:BAC
|
US | |
Palantir Technologies Inc
NYSE:PLTR
|
US | |
C
|
C3.ai Inc
NYSE:AI
|
US |
Uber Technologies Inc
NYSE:UBER
|
US | |
NIO Inc
NYSE:NIO
|
CN | |
Fluor Corp
NYSE:FLR
|
US | |
Jacobs Engineering Group Inc
NYSE:J
|
US | |
TopBuild Corp
NYSE:BLD
|
US | |
Abbott Laboratories
NYSE:ABT
|
US | |
Chevron Corp
NYSE:CVX
|
US | |
Occidental Petroleum Corp
NYSE:OXY
|
US | |
Matrix Service Co
NASDAQ:MTRX
|
US | |
Automatic Data Processing Inc
NASDAQ:ADP
|
US | |
Qualcomm Inc
NASDAQ:QCOM
|
US | |
Ambarella Inc
NASDAQ:AMBA
|
US |
This alert will be permanently deleted.
Intrinsic Value
The intrinsic value of one QURE stock under the Base Case scenario is 11.953 USD. Compared to the current market price of 5.905 USD, Uniqure NV is Undervalued by 51%.
The Intrinsic Value is calculated as the average of DCF and Relative values:
Valuation Backtest
Uniqure NV
Uncover deeper insights with the Valuation Backtest. Learn how current stock valuations stack up against historical averages to gauge true investment potential.
Start backtest now and learn if your stock is truly undervalued or overvalued!
Stock is trading at its lowest valuation over the past 5 years.
To access the results of this valuation backtest, please register an account with us. Registration is quick and gives you instant access to insights on 3 stocks per week for free.
The backtest for QURE cannot be conducted due to limitations such as insufficient data or other constraints. Please select a different stock or adjust your settings.
Fundamental Analysis
Select up to 3 indicators:
Select up to 3 indicators:
Months
Months
Months
Months
Select up to 2 periods:
Revenue & Expenses Breakdown
Uniqure NV
Balance Sheet Decomposition
Uniqure NV
Current Assets | 464.1m |
Cash & Short-Term Investments | 435.2m |
Receivables | 5.3m |
Other Current Assets | 23.6m |
Non-Current Assets | 181.7m |
Long-Term Investments | 28.3m |
PP&E | 40.4m |
Intangibles | 100.7m |
Other Non-Current Assets | 12.3m |
Current Liabilities | 71.3m |
Accounts Payable | 5.4m |
Accrued Liabilities | 34.2m |
Other Current Liabilities | 31.7m |
Non-Current Liabilities | 518.7m |
Long-Term Debt | 477.8m |
Other Non-Current Liabilities | 40.9m |
Earnings Waterfall
Uniqure NV
Revenue
|
28.6m
USD
|
Cost of Revenue
|
-26.5m
USD
|
Gross Profit
|
2m
USD
|
Operating Expenses
|
-196.8m
USD
|
Operating Income
|
-194.7m
USD
|
Other Expenses
|
-44.8m
USD
|
Net Income
|
-239.5m
USD
|
Free Cash Flow Analysis
Uniqure NV
USD | |
Free Cash Flow | USD |
QURE Profitability Score
Profitability Due Diligence
Uniqure NV's profitability score is 16/100. The higher the profitability score, the more profitable the company is.
Score
Uniqure NV's profitability score is 16/100. The higher the profitability score, the more profitable the company is.
QURE Solvency Score
Solvency Due Diligence
Uniqure NV's solvency score is 30/100. The higher the solvency score, the more solvent the company is.
Score
Uniqure NV's solvency score is 30/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
QURE Price Targets Summary
Uniqure NV
According to Wall Street analysts, the average 1-year price target for QURE is 19.38 USD with a low forecast of 7.07 USD and a high forecast of 29.4 USD.
Dividends
Current shareholder yield for QURE is .
Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?
Ownership
QURE Insider Trading
Buy and sell transactions by insiders
Period | Sold | Bought | Net |
---|---|---|---|
3 Months |
|
|
|
6 Months |
|
|
|
9 Months |
|
|
|
12 Months |
|
|
|
Profile
Country
Industry
Market Cap
Dividend Yield
Description
uniQure NV engages in the discovery, development, and commercialization of innovative gene therapies. The company is headquartered in Amsterdam, Noord-Holland and currently employs 463 full-time employees. The company went IPO on 2014-02-05. The company seeks to develop one-time administered treatments with potentially curative results for patients suffering from genetic and other devastating diseases. The company develops, both internally and through partnerships, a pipeline of gene therapies. The company produces adeno-associated virus based, or AAV-based, gene therapies in its own facilities with a proprietary, commercial-scale, current good manufacturing practices, compliant, manufacturing process. AMT-061, the Company’s lead product candidate for patients with hemophilia B, is going through a dosing phase of a pivotal study. AMT-130, the product candidate for patients with Huntington’s disease is in Phase I/II clinical study.
Contact
IPO
Employees
Officers
The intrinsic value of one QURE stock under the Base Case scenario is 11.953 USD.
Compared to the current market price of 5.905 USD, Uniqure NV is Undervalued by 51%.